GlassScriptPhysician profile
Manal Najar
NPI 1083734099
$1,090.83
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,091.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $249.49 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $225.83 | 2019 | |
| Pfizer INC. | $133.35 | 2019 | |
| Amarin Pharma, INC. | $124.99 | 2019 | |
| Amgen INC. | $97.93 | 2019 | |
| Lilly USA, LLC | $92.88 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.57 | 2019 | |
| Medtronic Vascular, INC. | $76.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manal Najar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.